Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 2 institutions in 1 country.
Monica L Brown LobbinsDepartments of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Imara-Safi O ScottDepartments of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Andrzej T SlominskiDepartments of Dermatology, University of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL 35294, USA.ORCID 0000-0001-8963-3995
Karen A HastyDepartments of Orthopedic Surgery and Biomedical Engineering, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Sicheng ZhangDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, TN 38163, USA.ORCID 0000-0003-3798-7550
Duane D MillerDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, TN 38163, USA.ORCID 0000-0002-6093-0985
Wei LiDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, TN 38163, USA.ORCID 0000-0002-9522-4474
Tae-Kang KimDepartments of Dermatology, University of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL 35294, USA.ORCID 0000-0003-1394-4134
Zorica JanjetovicDepartments of Dermatology, University of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL 35294, USA.ORCID 0000-0001-6108-2212
Tejesh S PatelDepartment of Dermatology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Linda K MyersDepartments of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Arnold E PostlethwaiteDepartments of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
University of Tennessee Health Science Center · USUniversity of Alabama at Birmingham · US
Funding
Mechanism of action and function of novel secosteroid 20(OH)D3 in the skinR01AR073004 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ANDRZEJ T SLOMINSKI · 2018 to 2026
$2.9M
Novel Biosynthetic Pathway for Secosteroids and the SkinR01AR052190 · NIAMS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI POSTLETHWAITE, ARNOLD E, SLOMINSKI, ANDRZEJ T · 2006 to 2013
$2.2M
Significance of metabolic activation of lumisterol in the skinR01AR071189 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SLOMINSKI, ANDRZEJ T · 2017 to 2021
$1.6M
Canonical and non-canonical vitamin D activation pathways in systemic lupusR21AI149267 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RAMAN, CHANDER, SLOMINSKI, ANDRZEJ T · 2020 to 2021
$408k
Mechanism of action of 20-hydroxyvitamin D3 in dermal fibroblastsR21AR066505 · NIAMS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI SLOMINSKI, ANDRZEJ T · 2014 to 2015
$355k
CYP11A1-derived secosteroids as therapeutic agents in UVB induced skin cancerI01BX004293 · VA · BIRMINGHAM VA MEDICAL CENTER · PI SLOMINSKI, ANDRZEJ T · 2019 to 2025
–
Arthritis Foundation program directed fundsBLRD VA I01 BX004293National Scleroderma Foundation program directed fundsNIAID NIH HHS R21 AI149267NIAMS NIH AR066505, AR071189, AR073004,NIAMS NIH HHS R01 AR052190NIAMS NIH HHS R01 AR071189NIAMS NIH HHS R01 AR073004NIAMS NIH HHS R21 AR066505VA S1P1BX001607
6 · The paper itself
Abstract
Systemic sclerosis (SSc; scleroderma) is a chronic fibrotic disease involving TGF-β1. Low serum vitamin D (vit D) correlates with the degree of fibrosis and expression of TGF-β1. This study was designed to determine whether the noncalcemic vit D analog, 17,20S(OH)
Indexed as
Disease Models, AnimalAnimalsAntibiotics, AntineoplasticBleomycinCholecalciferolCytokinesFemaleFibrosisMiceMice, Inbred C57BLScleroderma, SystemicSkin Diseases17,20-dihydroxypregnacalciferol-3,17,20-trihydroxy-9,10-secopregna-5,7,10-trieneAntibiotics, AntineoplasticBleomycinCholecalciferolCytokinesbleomycin model of fibrosiscollagencytokinessclerodermaTGF-β1vitamin D
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.